Cover Image


View/Hide Left Panel

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a MS vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is -$12,000. A negative value represents a saving in costs in addition to a saving in QALYs. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is -$11,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.


Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised Estimate of the Prevalence of Multiple Sclerosis in the United States. Annals of Neurology 1992; 31:333–336.

Koch-Henriksen N. Incidence of Multiple Sclerosis in Denmark 1948–1982: A Descriptive Nationwide Study. Neuroepidemiology 1992; 11:1–10.

Miller CM, Hens M. Multiple Sclerosis: A Literature Review. Journal of Neuroscience Nursing 1993; 25:174–179.

Multiple Sclerosis Foundation. 1997. Multiple Sclerosis Statistics. URL (accessed September 26, 1997).

Warren S, Warren KG. Prevalence, Incidence, and Characteristics of Multiple Sclerosis in Westlock County, Alberta, Canada. Neurology 1993; 43:1760–1763.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement